Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

Trial Profile

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms DARWIN1
  • Most Recent Events

    • 06 Nov 2018 Planned End Date changed from 1 Jan 2023 to 1 Nov 2023.
    • 06 Nov 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Nov 2023.
    • 19 Dec 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top